Ellery Mangas

Vice President Regulatory Affairs at Neurogene

Ellery Mangas has a wealth of experience in the field of regulatory affairs, spanning over 25 years. Currently, they hold the position of Vice President of Regulatory Affairs at Neurogene Inc. which they have held since March 2022. Prior to that, they served as the Executive Director of Regulatory Affairs at the same company since October 2020.

Before joining Neurogene Inc., Ellery worked at AGTC for five years, starting in 2015. During their time at AGTC, they held several positions, including Vice President of Regulatory Affairs and Quality Assurance from 2020 to 2020, Executive Director of Regulatory Affairs and Quality Assurance from 2018 to 2020, and Senior Director of Regulatory Affairs from 2015 to 2018.

Their career in regulatory affairs began at COR Therapeutics, Inc. in 1996, where they worked as an Associate I/II in Quality Control before transitioning to an Associate in Regulatory Affairs. Ellery then joined Nabi Biopharmaceuticals in 1999 as a Senior Manager of Regulatory Affairs. In 2006, they moved to Goodwin Biotechnology, Inc. as the Director of Regulatory and Quality.

Ellery's experience also includes their time at UCB, Inc. where they held the positions of Manager of Regulatory Affairs CMC from 2007 to 2010 and Associate Director of Regulatory Affairs from 2010 to 2015.

Throughout their career, Ellery Mangas has consistently demonstrated their expertise and leadership in regulatory affairs and quality assurance roles across various companies.

Ellery Mangas completed a Bachelor of Science degree in Microbiology and Cell Science, with a minor in Chemistry, at the University of Florida from 1990 to 1995. Later, in 2008 to 2009, Ellery pursued a Graduate Certificate in Regulatory Affairs at The University of Georgia.

Location

Gainesville, United States

Links


Org chart


Teams

This person is not in any teams


Offices

This person is not in any offices


Neurogene

Neurogene was founded to bring life-changing medicines to patients and families affected by rare neurological disorders. We partner with leading academic researchers, patient advocacy organizations and caregivers to bring to patients therapies that address the underlying genetic cause of a broad spectrum of neurological diseases where no effective treatment options exist today. Our lead programs use AAV-based gene therapy technology to deliver a normal gene to patients with a dysfunctional gene. Neurogene is also investing in novel technology to develop treatments for diseases not well served by gene therapy.


Industries

Employees

11-50

Links